# Compassionate Use of REGN-COV2 for the Treatment of COVID-19

> **NCT04617535** · — · NO_LONGER_AVAILABLE · sponsor: **Regeneron Pharmaceuticals**

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** REGN10933+REGN10987 combination therapy

## Key facts

- **NCT ID:** NCT04617535
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04617535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04617535, "Compassionate Use of REGN-COV2 for the Treatment of COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04617535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*